Researchers at Cancer Research Center Publish New Data on Antiretrovirals (Podophyllic Aldehyde, a Podophyllotoxin Derivate, Elicits Different Cell Cycle Profiles Depending on the Tumor Cell Line: A Systematic Proteomic Analysis).

Researchers at the Cancer Research Center in Salamanca, Spain have published a new report on antiretrovirals. The study focused on the compound podophyllic aldehyde, a cyclolignan derived from the natural product podophyllotoxin. The researchers found that podophyllic aldehyde exhibited increased cytotoxicity and more successful cell cycle blocking compared to the FDA-approved drug etoposide, another podophyllotoxin derivative. The compound also showed a selective antimitotic mechanism of action in certain tumor cell lines. These findings suggest that podophyllic aldehyde has potential as a new antitumor therapy and should be further studied and analyzed. [Extracted from the article]